US2023218799A1PendingUtilityA1

Biocompatible hydrogel treatments for retinal detachment

Assignee: C P MEDICAL CORPPriority: May 11, 2012Filed: Jan 10, 2023Published: Jul 13, 2023

Est. expiryMay 11, 2032(~5.8 yrs left)· nominal 20-yr term from priority

A61K 9/0051A61L 26/0019A61K 47/18A61K 47/20A61K 47/32A61K 47/38A61K 9/7015A61L 27/18A61L 27/52A61L 27/54A61L 24/0031A61L 24/046A61L 2300/402A61L 2300/406A61L 2300/41A61L 2300/416A61L 2300/418A61L 2430/16A61L 27/58A61L 24/0042C08J 2300/206A61L 2400/06A61P 27/02A61K 51/1213A61F 9/00727A61F 9/007A61L 26/0023A61L 26/0066A61L 26/008A61L 26/009

PatentIndex Score

Cited by

References

Claims

Abstract

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Claims

exact text as granted — not AI-modified

1 - 16 . (canceled)

17 . A composition for the treatment of retinal detachment, comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethylene glycol chain and terminates in a nucleophilic group selected from hydroxyl, thiol, and amino; (b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethylene glycol chain and terminates in an electrophilic group selected from an epoxide, maleimide, succinimidyl, and an alpha-beta unsaturated ester; and (c) a viscosity enhancer selected from the group consisting of hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium hyaluronate, polyvinyl alcohol, and polyvinylpyrrolidone;
wherein the composition polymerizes and/or gels when placed in the eye of a subject with retinal detachment.

18 . The composition of claim 17 , wherein the composition further comprises a buffer providing a pH range of about 6.0 to about 8.5.

19 . The composition of claim 17 , wherein the composition further comprises a therapeutic agent.

20 . The composition of claim 17 , wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from

and wherein n is 1-200.

21 . The composition of claim 17 , wherein the multi-ARM nucleophilic polyol monomers are selected from the group consisting of:

wherein R is hexaglycerol or tripentaerythritol and n is 1-200.

22 . The composition of claim 17 , wherein the electrophilic arms of the multi-ARM electrophilic polyol monomers are selected from the group consisting of:

wherein m is 2 or 3 and n is 1-200.

23 . The composition of claim 17 , wherein the multi-ARM electrophilic polyol monomers are selected from the group consisting of:

wherein R is hexaglycerol or tripentaerythritol and n is 1-200.

24 . The composition of claim 17 , wherein the composition comprises the following multi-ARM polyol monomers:

wherein R is hexaglycerol or tripentaerythritol; and
wherein n is such that the molecular weight of each of the polyol monomer is 20 kDa.

25 . The composition of claim 24 , wherein the multi-ARM polyol monomer is in a hydrochloride salt form.

26 . The composition of claim 17 , wherein the viscosity enhancer comprises sodium hyaluronate.

27 . The composition of claim 17 , wherein the composition further comprises a dye.

28 . A method of treating retinal detachment comprising delivering a composition of claim 17 to a site of a retinal tear in a human eye, the composition comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethylene glycol chain and terminates in a nucleophilic group selected from hydroxyl, thiol, and amino;
(b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethylene glycol chain and terminates in an electrophilic group selected from epoxide, maleimide, succinimidyl, and an alpha-beta unsaturated ester; and
(c) a viscosity enhancer selected from the group consisting of hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium hyaluronate, polyvinyl alcohol, and polyvinylpyrrolidone;

wherein the composition polymerizes and/or gels to form a biocompatible retinal patch to treat the retinal detachment in the patient.

29 . The method of claim 28 , wherein the composition further comprises a buffer providing a pH range of about 6.0 to about 8.5.

30 . The method of claim 28 , wherein the composition further comprises a therapeutic agent.

31 . The method of claim 28 , wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from the group consisting of

wherein n is 1-200.

32 . The method of claim 28 , wherein the multi-ARM nucleophilic polyol monomers are selected from the group consisting of:

wherein R is hexaglycerol or tripentaerythritol and n is 1-200.

33 . The method of claim 28 , wherein the composition comprises the following multi-ARM polyol monomers:

wherein R is hexaglycerol or tripentaerythritol and n is 1 to 200.

34 . The method of claim 33 , wherein the multi-ARM polyol monomer is in a hydrochloride salt form.

35 . The method of claim 28 , wherein the viscosity enhancer comprises sodium hyaluronate.

36 . The method of claim 28 , wherein the composition further comprises a dye.

Join the waitlist — get patent alerts

Track US2023218799A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.